Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sonnet Biotherapeutics Holdings Inc SONN

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as... see more

NDAQ:SONN - Post Discussion

Sonnet Biotherapeutics Holdings Inc > BTFD !!!!!!!!!!!!!!
View:
Post by Iseneschal on Apr 30, 2021 9:52am

BTFD !!!!!!!!!!!!!!

Sub - $2 is a buying opportunity

 JMHO
Comment by Iseneschal on Apr 30, 2021 10:56am
LoL....now a big bid shows up at $2.......smoke & mirrors or is it "the real deal " Time will tell
Comment by Iseneschal on Apr 30, 2021 11:11am
Yes sir....it was real...but funny as it is.....it got filled....1 block of almost 15,000 shares Interesting......why do I smell a rat.  Cheers !
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities